Additional Relevant Details Professor Olivier Hermine said: "We will present results from the masitinib international AB06006 study, which was the first ever phase 3 prospective, randomized, placebo-controlled study of a treatment for severe indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis. There is currently no registered or established standard treatment for this rare condition with high unmet medical need. Study AB06006 successfully achieved all of its primary and secondary objectives. The study also generated positive results on the pre-specified objective markers of mast cell activation. Masitinib may therefore be an important new treatment option for these patients; moreover, both efficacy and safety data indicate a possibility for effective long-term management of this difficult-to-treat condition."